This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Vapotherm Beheer

Beheer criteriumcontroles 4/4

De CEO Vapotherm is Joe Army, benoemd in Jun2012, heeft een ambtstermijn van 12.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 776.25K, bestaande uit 65.5% salaris en 34.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 6.93% van de aandelen van het bedrijf, ter waarde $ 943.47K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 4.7 jaar.

Belangrijke informatie

Joe Army

Algemeen directeur

US$776.3k

Totale compensatie

Percentage CEO-salaris	65.5%
Dienstverband CEO	12.3yrs
Eigendom CEO	6.9%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	4.7yrs

Recente managementupdates

The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares

Mar 12

Recent updates

Vapotherm announces $23M private placement

Feb 08

Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02M

Nov 02

The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares

Mar 12

Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last Year

Mar 11

Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?

Jan 19

Vapotherm guides Q4 revenue above consensus, ~212% Y/Y growth

Jan 13

Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On Shares

Dec 14

Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%

Dec 11

Vapotherm shares +9% on higher Q4 guidance

Dec 01

Vapotherm: The Game Has Completely Changed

Nov 13

Analyse CEO-vergoeding

Hoe is Joe Army's beloning veranderd ten opzichte van Vapotherm's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$54m
Mar 31 2024	n/a	n/a	-US$55m
Dec 31 2023	US$776k	US$509k	-US$58m
Sep 30 2023	n/a	n/a	-US$69m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$108m
Dec 31 2022	US$4m	US$572k	-US$113m
Sep 30 2022	n/a	n/a	-US$110m
Jun 30 2022	n/a	n/a	-US$98m
Mar 31 2022	n/a	n/a	-US$72m
Dec 31 2021	US$3m	US$538k	-US$60m
Sep 30 2021	n/a	n/a	-US$58m
Jun 30 2021	n/a	n/a	-US$57m
Mar 31 2021	n/a	n/a	-US$48m
Dec 31 2020	US$3m	US$433k	-US$52m
Sep 30 2020	n/a	n/a	-US$47m
Jun 30 2020	n/a	n/a	-US$47m
Mar 31 2020	n/a	n/a	-US$52m
Dec 31 2019	US$3m	US$400k	-US$51m
Sep 30 2019	n/a	n/a	-US$51m
Jun 30 2019	n/a	n/a	-US$48m
Mar 31 2019	n/a	n/a	-US$47m
Dec 31 2018	US$625k	US$300k	-US$43m
Sep 30 2018	n/a	n/a	-US$39m
Jun 30 2018	n/a	n/a	-US$37m
Mar 31 2018	n/a	n/a	-US$33m
Dec 31 2017	US$545k	US$275k	-US$31m

Compensatie versus markt: De totale vergoeding ($USD 776.25K ) Joe } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Joe is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Joe Army (60 yo)

12.3yrs

Tenure

US$776,254

Compensatie

Mr. Joseph F. Army, also known as Joe, CPA has been the Chief Executive Officer and President of Vapotherm, Inc. since June 26, 2012. Mr. Army serves as Advisor of Physician 360, Inc. He served as the Chie...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Joseph Army	CEO, President & Director	12.3yrs	US$776.25k	6.93% $ 943.5k
John Landry	Senior VP	12.1yrs	US$721.06k	0.76% $ 102.9k
Brian Lawrence	Senior VP & CTO	2.8yrs	US$744.63k	0.37% $ 49.9k
William Niland	Founder	no data	geen gegevens	geen gegevens
Dorota Mckay	VP, Controller & Chief Accounting Officer	2.8yrs	geen gegevens	0.074% $ 10.1k
Anthony Haagen	Vice President of Legal & Compliance	no data	geen gegevens	geen gegevens
James Lightman	Senior VP	3.8yrs	geen gegevens	geen gegevens
Lindsay Becker	Vice President of Human Resources	8.3yrs	geen gegevens	geen gegevens
Jessica Whittle	Chief Medical Officer & VP of Clinical Research	1.7yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VAPO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joseph Army	CEO, President & Director	12.3yrs	US$776.25k	6.93% $ 943.5k
James Liken	Independent Chairman of the Board	14.3yrs	US$98.38k	1.09% $ 147.8k
Elizabeth Weatherman	Independent Director	6.9yrs	US$68.38k	1.54% $ 209.5k
Lance Berry	Independent Director	4.7yrs	US$68.38k	0.36% $ 49.0k
Donald Spence	Independent Director	3.9yrs	US$68.38k	0.16% $ 21.1k
Lori Knowles	Independent Director	3.3yrs	US$55.88k	0.13% $ 17.1k
Mary Moynihan	Independent Director	3.3yrs	US$58.38k	0.13% $ 18.2k

4.7yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VAPO wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).

This company has been acquired

Vapotherm Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Vapotherm, Inc., Annual General Meeting, Jun 21, 2022

Senior VP notifies of intention to sell stock

Senior VP & Chief Commercial Officer exercised options and sold US$170k worth of stock

Insider recently bought US$4.8m worth of stock

Independent Chairman of the Board recently bought US$170k worth of stock

The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares

Recent updates

Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC completed the acquisition of Vapotherm, Inc. (OTCPK:VAPO) from a group of shareholders.

Perceptive Discovery Fund LP, managed by Perceptive Advisors LLC entered into definitive merger agreement to acquire Vapotherm, Inc. (OTCPK:VAPO) for $15.1 million.

Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADE

The New York Stock Exchange to Commence Delisting Proceedings against Vapotherm

Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023

Vapotherm, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Vapotherm Announces Presentation of an Investigator-Initiated Clinical Trial, 'High Flow Humidified Oxygen as an Early Intervention in Children with Acute Severe Asthma - a Feasibility Randomized Controlled Trial' at the European Respiratory Society International Congress 2023

Vapotherm, Inc. Revises Earnings Guidance for Fiscal 2023

Vapotherm, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Vapotherm, Inc. Reports Impairment of Long-Lived and Intangible Assets for the First Quarter Ended March 31, 2023

Vapotherm Receives Price Cure Notification Letter from the NYSE Indicates its Stock Price Above the NYSE's Minimum Requirement

Vapotherm, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Vapotherm announces $23M private placement

Vapotherm, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Vapotherm, Inc. Provides Revenue Guidance for 2022

Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02M

Vapotherm, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Vapotherm Announces NYSE Continued Listing Standard Notice

Vapotherm draws downgrade at William Blair after 2Q results

Vapotherm, Inc. Reports Unaudited Condensed Consolidated Impairment Charges for the Second Quarter Ended June 30, 2022

Vapotherm, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Vapotherm, Inc. Plans to Move All of Its Manufacturing Operations from New Hampshire to Mexico

Price target decreased to US$4.83

Vapotherm, Inc.(NYSE:VAPO) dropped from Russell 2000 Growth Index

Vapotherm: Out Of Air

Vapotherm, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Vapotherm, Inc., Annual General Meeting, Jun 21, 2022

Vapotherm, Inc. Provides Revenue Guidance for the First Quarter of 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$34.33

Vapotherm, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Vapotherm, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Is Vapotherm (NYSE:VAPO) Using Too Much Debt?

Vapotherm, Inc. Announces Revenue Guidance for the Fourth Quarter of 2021, Full Year 2021 and 2022

Third quarter 2021 earnings released: US$0.52 loss per share (vs US$0.49 loss in 3Q 2020)

Chief Accounting Officer Joel Dube has left the company

Vapotherm, Inc. Revises Revenue Guidance for the Fiscal Year 2021

Vapotherm, Inc. Announces FDA 510(k) Clearance for HVT 2.0 Next Generation Platform

Senior VP notifies of intention to sell stock

Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.35 loss in 2Q 2020)

Senior VP & Chief Commercial Officer exercised options and sold US$170k worth of stock

Vapotherm: Hardly Breathing Room

Insider recently bought US$4.8m worth of stock

Independent Director Marina Hahn has left the company

Independent Chairman of the Board recently bought US$170k worth of stock

Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?

First quarter 2021 earnings released: US$0.40 loss per share (vs US$0.66 loss in 1Q 2020)

Vapotherm, Inc. Provides Financial Guidance for 2021

Vapotherm reports Q1 results

The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares

Independent Director recently bought US$109k worth of stock

Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last Year

Full year 2020 earnings released: US$2.16 loss per share (vs US$2.74 loss in FY 2019)

Revenue and earnings beat expectations

New 90-day low: US$23.17

Vapotherm, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Senior VP & Chief Commercial Officer notifies of intention to sell stock

Senior VP & Chief Commercial Officer exercised options and sold US$56k worth of stock

Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?

Vapotherm guides Q4 revenue above consensus, ~212% Y/Y growth

New 90-day high: US$32.08

Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On Shares

Insider recently bought US$217k worth of stock

Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%

Analysts update estimates

Vapotherm, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year 2020

Vapotherm shares +9% on higher Q4 guidance